Alteration of Visuospatial System as an Early Marker of Cognitive Decline: A Double-Center Neuroimaging Study

Berente, Dalida Borbála; Zsuffa, Janos; Werber, Tom; Kiss, Máté G.; Drotos, Anita; Kamondi, Anita; Csukly, Gábor; Horváth, András

doi:10.3389/fnagi.2022.854368

Cited by 2 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BVMT-R is associated with right hemisphere visual networks in MS ( Fuchs et al, 2019 ). Visual spatial function in middle age has emerged as the main predictor of cognitive decline later in life, and this correlation has been hypothesized as the first measurable decline ( Possin, 2010 ; Salimi et al, 2018 ; Kolli et al, 2021 ; Berente et al, 2022 ). Informed by the underlying cell biology of CHRFAM7A, the association between visual spatial function and cognitive decline could be driven by a more resilient neuronal structure measured by the visual spatial relative strength, latently detecting CHRFAM7A direct allele carriers.…”

Section: Discussionmentioning

confidence: 99%

Human restricted CHRFAM7A gene increases brain efficiency

Jakimovski,

Dorn,

Regno

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

IntroductionCHRFAM7A, a uniquely human fusion gene, has been associated with neuropsychiatric disorders including Alzheimer’s disease, schizophrenia, anxiety, and attention deficit disorder. Understanding the physiological function of CHRFAM7A in the human brain is the first step to uncovering its role in disease. CHRFAM7A was identified as a potent modulator of intracellular calcium and an upstream regulator of Rac1 leading to actin cytoskeleton reorganization and a switch from filopodia to lamellipodia implicating a more efficient neuronal structure. We performed a neurocognitive-MRI correlation exploratory study on 46 normal human subjects to explore the effect of CHRFAM7A on human brain.MethodsDual locus specific genotyping of CHRFAM7A was performed on genomic DNA to determine copy number (TaqMan assay) and orientation (capillary sequencing) of the CHRFAM7A alleles. As only the direct allele is expressed at the protein level and affects α7 nAChR function, direct allele carriers and non-carriers are compared for neuropsychological and MRI measures. Subjects underwent neuropsychological testing to measure motor (Timed 25-foot walk test, 9-hole peg test), cognitive processing speed (Symbol Digit Modalities Test), Learning and memory (California Verbal Learning Test immediate and delayed recall, Brief Visuospatial Memory Test—Revised immediate and delayed recall) and Beck Depression Inventory—Fast Screen, Fatigue Severity Scale. All subjects underwent MRI scanning on the same 3 T GE scanner using the same protocol. Global and tissue-specific volumes were determined using validated cross-sectional algorithms including FSL’s Structural Image Evaluation, using Normalization, of Atrophy (SIENAX) and FSL’s Integrated Registration and Segmentation Tool (FIRST) on lesion-inpainted images. The cognitive tests were age and years of education-adjusted using analysis of covariance (ANCOVA). Age-adjusted analysis of covariance (ANCOVA) was performed on the MRI data.ResultsCHRFAM7A direct allele carrier and non-carrier groups included 33 and 13 individuals, respectively. Demographic variables (age and years of education) were comparable. CHRFAM7A direct allele carriers demonstrated an upward shift in cognitive performance including cognitive processing speed, learning and memory, reaching statistical significance in visual immediate recall (FDR corrected p = 0.018). The shift in cognitive performance was associated with smaller whole brain volume (uncorrected p = 0.046) and lower connectivity by resting state functional MRI in the visual network (FDR corrected p = 0.027) accentuating the cognitive findings.ConclusionThese data suggest that direct allele carriers harbor a more efficient brain consistent with the cellular biology of actin cytoskeleton and synaptic gain of function. Further larger human studies of cognitive measures correlated with MRI and functional imaging are needed to decipher the impact of CHRFAM7A on brain function.

show abstract